Promethazine HClCAS# 58-33-3 |
- Pregnenolone
Catalog No.:BCN6255
CAS No.:145-13-1
- Adrenosterone
Catalog No.:BCC4061
CAS No.:382-45-6
- Epiandrosterone
Catalog No.:BCC4481
CAS No.:481-29-8
- Cortisone acetate
Catalog No.:BCC4771
CAS No.:50-04-4
- Deoxycorticosterone acetate
Catalog No.:BCC4655
CAS No.:56-47-3
Quality Control & MSDS
3D structure
Package In Stock
Number of papers citing our products
| Cas No. | 58-33-3 | SDF | Download SDF |
| PubChem ID | 6014 | Appearance | Powder |
| Formula | C17H21ClN2S | M.Wt | 320.88 |
| Type of Compound | N/A | Storage | Desiccate at -20°C |
| Solubility | H2O : 100 mg/mL (311.64 mM; Need ultrasonic) DMSO : 50 mg/mL (155.82 mM; Need ultrasonic) | ||
| Chemical Name | N,N-dimethyl-1-phenothiazin-10-ylpropan-2-amine;hydrochloride | ||
| SMILES | CC(CN1C2=CC=CC=C2SC3=CC=CC=C31)N(C)C.Cl | ||
| Standard InChIKey | XXPDBLUZJRXNNZ-UHFFFAOYSA-N | ||
| Standard InChI | InChI=1S/C17H20N2S.ClH/c1-13(18(2)3)12-19-14-8-4-6-10-16(14)20-17-11-7-5-9-15(17)19;/h4-11,13H,12H2,1-3H3;1H | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
| Description | Promethazine Hcl(NSC-231688) is the first-generation antihistamine; strong antagonist of the H1 receptor and moderate mACh receptor antagonist, moderate affinity for 5-HT2A, 5-HT2C, D2 and α1-adrenergic receptors. References: | |||||
Promethazine HCl Dilution Calculator
Promethazine HCl Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 3.1164 mL | 15.5821 mL | 31.1643 mL | 62.3286 mL | 77.9107 mL |
| 5 mM | 0.6233 mL | 3.1164 mL | 6.2329 mL | 12.4657 mL | 15.5821 mL |
| 10 mM | 0.3116 mL | 1.5582 mL | 3.1164 mL | 6.2329 mL | 7.7911 mL |
| 50 mM | 0.0623 mL | 0.3116 mL | 0.6233 mL | 1.2466 mL | 1.5582 mL |
| 100 mM | 0.0312 mL | 0.1558 mL | 0.3116 mL | 0.6233 mL | 0.7791 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
New product
- Desipramine hydrochloride
Catalog No.:BCC7553
CAS No.:58-28-6
- Menadione
Catalog No.:BCN8351
CAS No.:58-27-5
- Testosterone
Catalog No.:BCN2193
CAS No.:58-22-0
- Testosterone cypionate
Catalog No.:BCC9167
CAS No.:58-20-8
- Methyltestosterone
Catalog No.:BCC9045
CAS No.:58-18-4
- Aminophenazone
Catalog No.:BCC8815
CAS No.:58-15-1
- Pyrimethamine
Catalog No.:BCC2307
CAS No.:58-14-0
- Caffeine
Catalog No.:BCN5807
CAS No.:58-08-2
- Bax inhibitor peptide P5
Catalog No.:BCC2393
CAS No.:579492-83-4
- Bax inhibitor peptide V5
Catalog No.:BCC2394
CAS No.:579492-81-2
- Officinalisinin I
Catalog No.:BCN2825
CAS No.:57944-18-0
- L(+)-Asparagine Monohydrate
Catalog No.:BCC8332
CAS No.:5794-13-8
- Prochlorperazine
Catalog No.:BCC3846
CAS No.:58-38-8
- Tetrabenazine
Catalog No.:BCC5277
CAS No.:58-46-8
- Theophylline
Catalog No.:BCN1258
CAS No.:58-55-9
- Pyridoxine HCl
Catalog No.:BCC4835
CAS No.:58-56-0
- Puromycin dihydrochloride
Catalog No.:BCC7860
CAS No.:58-58-2
- Puromycin aminonucleoside
Catalog No.:BCC1873
CAS No.:58-60-6
- Adenosine
Catalog No.:BCN5796
CAS No.:58-61-7
- Inosine
Catalog No.:BCN3841
CAS No.:58-63-9
- Papaverine
Catalog No.:BCC8230
CAS No.:58-74-2
- Biotin
Catalog No.:BCC3585
CAS No.:58-85-5
- D-(+)-Xylose
Catalog No.:BCN1010
CAS No.:58-86-6
- Hydrochlorothiazide
Catalog No.:BCC4786
CAS No.:58-93-5
Development of extended release coevaporates and coprecipitates of promethazine HCl with acrylic polymers: formulation considerations.[Pubmed:18379098]
Chem Pharm Bull (Tokyo). 2008 Apr;56(4):504-8.
The present investigation studied a novel extended release system of promethazine hydrochloride (PHC) with acrylic polymers Eudragit RLPO and Eudragit RS100 in different weight ratios (1 : 1 and 1 : 5) using coevaporation and coprecipitation techniques. Solid dispersions were characterized by Fourier-transformed infrared spectroscopy (FT-IR), Differential scanning calorimetry (DSC), Powder X-ray diffractometry (PXRD), Nuclear magnetic resonance (NMR), Scanning electron microscopy (SEM) as well as solubility and in vitro dissolution studies in 0.1 n HCl (pH 1.2), double distilled water and phosphate buffer (pH 7.4). Adsorption test from drug solution to solid polymers were also performed. Selected solid dispersion system was subjected to direct compression and compressed tablets were evaluated for in vitro dissolution studies. The progressive disappearance of drug peaks in thermotropic profiles of coevaporates were related to increasing amount of polymers while SEM studies suggested homogenous dispersion of drug in polymer. Eudragit RLPO had a greater adsorptive capacity than Eudragit RS100 and thus its coevaporates in 1 : 5 ratio exhibited higher dissolution rate with 91.90% drug release for 12 h. Among different formulations, tablets prepared by Eudragit RLPO coevaporates (1 : 5) displayed extended release of drug for 12 h with 90.87% release followed by zero order kinetics (r(2)=0.9808).
Microcapsule-gel formulation of promethazine HCl for controlled nasal delivery: a motion sickness medication.[Pubmed:17454422]
J Microencapsul. 2007 Mar;24(2):109-16.
The current method of choice for astronauts to treat space motion sickness is an intra-muscular injection of promethazine hydrochloride (PMZ HCl) which is invasive and causes considerable local irritation and discomfort at the site of injection. Intra-nasal delivery is considered a feasible alternative route for administration of medications to treat space motion sickness. The purpose of this research is to develop a PMZ HCl formulation that can be administered intra-nasally without irritation (i.e. leukocyte infiltration) in the nasal epithelium when dosed at PMZ HCl concentrations greater than the cytotoxic limit. The biocompatibility of PMZ HCl was tested in vitro and was shown to be cytotoxic at concentrations greater than 10(-5) molar regardless of pH. A controlled-release microencapsulated dosage formulation was developed using spinning disk atomization and release rates for the PMZ HCl microcapsules were determined in phosphate buffered saline. An animal study was conducted to determine the irritation response of rat nasal mucosa when dosed with encapsulated and non-encapsulated PMZ HCl.
A new spectrophotometric method for the determination of promethazine-HCl from pure and pharmaceutical preparations.[Pubmed:18970252]
Talanta. 2005 Oct 31;67(5):869-72.
Promethazine-HCl reacts with potassium persulphate to give a pinkish red color complex exhibiting maximum absorbance at 515nm. The reaction is selective for promethazine-HCl, with 1mug/mL as visual limit of identification and provides a basis for a new spectrophotometric determination method. The color forming reaction obeys Beer's Law from 0.001 to 0.125mg/mL of promethazine-HCl. The relative standard deviation does not exceed 0.005mg/mL. The method is successfully applied to pure and pharmaceutical formulations of promethazine-HCl. The quantitative assessment of tolerable amounts of possible interferants was also studied. The results are reproducible within +/-1% and in good agreement with those obtained by the standard procedure.
Development of a melting tablet containing promethazine HCl against motion sickness.[Pubmed:18770049]
AAPS PharmSciTech. 2008;9(3):1006-15.
The purpose of this study was to design a 'Traveller Friendly Drug Delivery System' for PM-HCl. Conventional promethazine (PM-HCl) tablets are bitter, need to be taken 1 h before symptoms and water is also needed. Taste-masked granules were produced with Eudragit E100 by extrusion, and analyzed with FTIR, DSC, and XRD. Tablets formulated from granules by direct compression using Ac-Di-Sol, Polyplasdone-XL, Primojel and ion-exchanger Tulsion339 and evaluated for mass uniformity, friability, tensile strength, drug content uniformity, water absorption ratio, in-vitro and in-vivo disintegration time and in-vitro dissolution studies. The observed drug-polymer interactions and reduced crystallinity may be reasons for increased dissolution rates. The formulated tablets were disintegrated within 15 s. Tablets (25 mg PM-HCl) with Ac-Di-Sol (4%) showed complete release within 1 min, while marketed conventional tablets (Phenergan; Rhone-Poulec) release 25% during the same period. A preliminary stability studies for the prepared tablets carried at 30 +/- 2 degrees C/60 +/- 5% RH, and 40 +/- 2 degrees C/75 +/- 5%RH for 3 months showed no significant changes in the tablets quality at 30 +/- 2 degrees C/60 +/- 5% RH. However, at 40 +/- 2 degrees C/75 +/- 5%RH marked increase in in-vitro disintegration time, tensile strength and decrease in friability and water absorption ratio was found. The present studies indicate the abilities of Eudragit E 100 for taste masking and improving the dissolution profile of PM-HCl after complexation. In addition, by employing cost effective direct compression method, fast-dissolving tablets of 400 mg total weight with an acceptable quality could be prepared.
